MMF as Immunosuppressive Therapy in IgA Nephropathy

Introduction: IgA Nephropathy (IgAN) is the most common cause of primary glomerulonephritis in developed countries. Treatment with ACEI/ARB has strong evidence in managing IgAN. If there is evidence of progression, immunosuppression is recommended. KDIGO guidelines do not advise Mycophenolate Mofetil’s (MMF) use in non-Chinese population currently. Methods: In this study, we reviewed immunosuppression with MMF retrospectively in IgAN patients managed at the Sussex Kidney Unit (SKU) – Brighton – United Kingdom. This was assessed using the primary measures of renal survival without requiring renal replacement therapy (RRT) and proteinuria reduction to >50% of the diagnosis baseline. Twenty-five patients diagnosed with IgAN between 2011 and 2020 and had been treated with MMF were retrospectively reviewed. Data was collected until January 2023, including laboratory results, histopathology, clinic letters, and medication. For those on RRT, data was collected up until the start of RRT. Results: Twenty- Five patients were reviewed; 24 were white Caucasians, and 1 was ethnically Asian. MMF was used in all 25 patients. Three patients were treated with MMF alone and 17 in combination with steroids. Five patients had prednisolone and cyclophosphamide for three months, followed by MMF maintenance. The average treatment duration was 2 years, and the average dose was 1g BD. Five patients progressed to end-stage renal disease (ESRD), and 3 had renal transplants. Twenty patients maintained renal survival; the mean eGFR at diagnosis was 45.6+/-34.1 and, at the time of review, was 56.1+/-26.6. Of the 17 patients who presented with AKI, 5 recovered to normal renal function, 5 had end-stage renal disease (ESRD), 4 had improvements, and 3 showed a decrease in eGFR. Overall, 70.6% of AKI patients recovered to normal or CKD levels. Eighty % of the patients had renal survival without RRT during the review. Twenty patients achieved more than 50% reduction of proteinuria, with five patients having proteinuria less than 0.3 g/24 hours and nine patients less than 0.5 g/24 hours. Comparison between the proteinuria at diagnosis and at the assessment time was significant (P<0.001). Conclusions: Mycophenolate mofetil effectively maintained renal survival and improved proteinuria in IgA nephropathy patients indicated for immunosuppression. The treatment was well tolerated by all patients.